INOVIQ Exosome Diagnostic Solutions

SubB2M/CA125 Test | Ovarian Cancer monitoring Progressing towards clinical validation For personal use only Ovarian cancer Unmet medical need Disruptive technology Intended use ⚫ #8 cancer in women & deadliest gynaecological cancer • 314k new cases of ovarian cancer worldwide pa¹ ⚫823k survivors (5-year)1 • Earlier and more accurate detection and monitoring tests required for ovarian cancer ⚫ US$1.8b global diagnostics market² • SubB2M is an engineered protein that specifically binds the pan-cancer biomarker Neu5Gc • Improved immunoassay for detection of Neu5Gc decorated CA125 • Increased sensitivity and specificity to detect cancer over existing assays • Aid in monitoring ovarian cancer treatment response and disease recurrence in women previously diagnosed with disease Go-to-market strategy •⚫LDT then IVD (510k/PMA process) • Partner with a CLIA-accredited laboratory Development stage Feasibility Completed Assay development H2 CY23 Analytical validation H2 CY23 Clinical validation H2 CY23 Monitoring study H1 CY24 LDT partner ready Jun 2024 13 1. Cancer Today (iarc.fr); 2. Ovarian Cancer Diagnostics Market Size Worth US$ 1.8 Bn by (globenewswire.com) INOVIQ

View entire presentation